References
- Ahtee L, Buncombe G. 1974. Metoclopramide induces catalepsy and increases striatal homovanillic acid content in mice. Acta Pharmacol Toxicol (Copenh) 35:429–432.
- Baer JT, Sauer WH, Berlin JA, Kimmel SE. 2004. Comparison of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of myocardial infarction in hypertensive patients. Am J Cardiol 94:479–481.
- Bhattacharya SK, Rao PJRM, Brumleve SJ Parmar SS. 1986. Role of putative neurotransmitters in bradykinin-induced catalepsy in the rat. Pharmaceut Res 3:162–166.
- Barnes NM, Champaneria S, Costall B, Kelly ME, Murphy DA, Naylor RJ. 1990. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1:239–242.
- Brown DC, Steward LJ, Ge J, Barnes NM. 1996. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 118:414–420.
- Campbell DJ, Kladis A, Valentijn AJ. 1995. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26:233–240.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. J Am Med Assoc 289:2560–2572.
- Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544.
- Georgiev V, György L, Getova D, Markovska V. 1985. Some central effects of angiotensin II. Interactions with dopaminergic transmission. Acta Physiol Pharmacol Bulg 11:19–26.
- Jenkins TA, Mendelsohn FA, Chai SY. 1997. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem 68:1304–1311.
- Jenkins TA, Wong JY, Howells DW, Mendelsohn FA, Chai SY. 1999. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J Neurochem 73:214–219.
- Lee E. 2009. Clinical anti-psychotic trials of intervention effectiveness in schizophrenia: Selective review on clinical outcomes. Hong Kong J Psychiat 19:26–29.
- Lewis EJ, Lewis JB. 2004. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner? J Am Soc Nephrol 15:1358–1360.
- Mendelsohn FA, Jenkins TA, Berkovic SF. 1993. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res 613:221–229.
- Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. 2008. Extrapyramidal side effects of anti-psychotics in a randomized trial. Br J Psychiat 193:279–288.
- Nair V, Arjuman A, Gopalakrishna HN, Nandini M. 2008. Effect of Withania somnifera root extract on haloperidol-induced catalepsy in albino mice. Phytother Res 22:243–246.
- Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. 2006. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15–22.
- Pires JG, Silva SR, Futuro-Neto HA. 1996. Effects of losartan on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 29:1045–1047.
- Przesmycki K, Kleinrok Z. 1976. The effect of bradykinin on central dopamine receptors. Pol J Pharmacol Pharm 28:673–678.
- Raghavendra V, Chopra K, Kulkarni SK. 1998. Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan. Neuropeptides 32:275–280.
- Sanberg PR. 1980. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284:472–473.